Longboard Pharmaceuticals

MRI of the brain
#epilepsy #Longboard Pharmaceuticals #Lundbeck #Mergers and acquisitions #Neurology

Acquisition to strengthen neuroscience pipeline

Lundbeck and Longboard Pharmaceuticals have announced an agreement for Lundbeck to acquire Longboard. Longboard is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases. Its lead asset, bexicaserin, has shown encouraging anti-seizure reduction to date in preclinical and clinical studies, with its next-generation superagonist mechanism specifically targeting… Read More

#Business & Investment #News